Tampilkan postingan dengan label FDA. Tampilkan semua postingan
Tampilkan postingan dengan label FDA. Tampilkan semua postingan

Jumat, 01 September 2017

$475,000 is a good deal for Kymriah, and a bad sign for controlling health care costs

$475,000 is a good deal for Kymriah, and a bad sign for controlling health care costs

Today's Managing Health Care Costs Number is $475,000

Personalized medicine is here - and it's a miracle.  Novartis' newly-approved drug Kymriah is genetically engineered immune cells from the patient which will kill leukemia cells, and it's shown remarkable efficacy in small trials.  One girl was dying of leukemia five years ago and remains in remission, and gave stirring testimony for the drug's approval before the FDA last month. (Photo of Emily Whitehead, above, is from the Associated Press via the NY Times)

This is just the beginning - training one's own immune cells to fight cancer (and possibly other diseases) holds enormous promise.  The cost: $475,000 for the one-time treatment.

Here are the reasons we shouldn't worry about that eye-popping cost

  • $475,000 is a small price to pay for a cure of an otherwise fatal disease- especially in a kid.  With a life expectancy of 70 years, this could mean the cost per Quality Adjusted  Life Year (QALY) is under $7000.
  • The drug has been approved for a rare cancer- with under 60 people likely to be eligible each year.  If all of them responded and paid full price, that's under $30 million.   Putting this in perspective, this is 0.0008% of national health care expenditures.
  • Novartis will restrict use to just 30-35 centers, so we won't have unqualified physicians prescribing this willy-nillly.  The engineered cells can cause life-threatening reactions - so this is an important safety measure
  • Novartis has promised refunds if there is no response in 1 month, and has also promised financial assistance for families without insurance coverage

You can probably guess that I'm worried, though.

Kymriah is the first of a set of CAR-T therapies - and there are a gaggle more on the way.  Some of them will be used for much more common conditions, and even Kymriah is likely to be used much more widely than the FDA-approved indications.   Gilead Pharmaceuticals just paid $11 billion for Kite, a cancer therapy company that has a CAR-T therapy tailored to non-Hodgkins Lymphoma expected to be approved in the next year.  The cost is likely to be similar, and the market larger. The total cost for CAR-T therapies will likely rise to many billions in just a few years.

Novartis has broken yet another price ceiling -and this will make it easier for the prices of other oncology medicines to continue to rise.   See this post for how this works with Multiple Sclerosis drugs.

Refunds for non-efficacy sound good in theory - but are often ineffective in practice.  This research showed "such schemes have poorly contributed to the fulfillment of the purpose in Italy, producing a trifling refund."

Financial assistance programs have largely been focused on maintaining price discipline - and have helped contribute to pharmaceutical company bottom lines by increasing revenue from other payers and offering the pharmas favorable tax treatment.

These genetically engineered cells will never be produced by a generic company - and are unlikely even to be produced as biosimilars for a long time if ever.   So if very high prices "stick," we should expect to pay them for the foreseeable future.

We should celebrate - this is an enormous feat of American medicine.  The initial research was performed at the University of Pennsylvania - but this drug would never had made it to market without the investment, trials, and regulatory work done by Novartis.

But we need to address drug prices if we are to control health care costs, and the high price set for Kymriah  is a bad omen.

Senin, 07 Agustus 2017

Bringing down pharmaceutical costs

Bringing down pharmaceutical costs


Today's Managing Health Care Costs Number is  250%

One area of bipartisan agreement is the desire to lower pharmaceutical prices.   As always, there are good ideas with downsides, bad ideas with upsides, and many ideas that are likely to  have unanticipated consequences.   Annual prescription drug costs are expected to increase to $597 billion by 2025- a 250% increase from 2007, so there is a real imperative to address pharmaceutical costs. 

Among the ideas that are being discussed:

  1. Ease regulatory burden to allow faster generics to market. 
    The real problem here has generally been litigation from incumbent brand name products and lack of competition for non-blockbuster generics, most of which have only 1 or 2 manufacturers - leaving them vulnerable to steep price increases.  Let's make it harder to take legal steps to block new generics, easier to get approval for biosimilars, and allow importation of generics from other countries with good regulatory schemes when there is a shortage.
     
  2. Allow 'value based pricing.'
    No one is preventing value based pricing now- but we should think hard about whether this is really what we want.   Airlines use value based pricing (so that business travelers not staying over a Saturday night pay higher prices).   Some pharmaceutical companies want to be able to charge different prices based on the indication for a drug - but this is likely to lead to higher overall costs (and huge administrative headaches).  Her's a pretty positive assessment of  indication specific pricing from ICER (2015), and here's a perspective from New England Journal of Medicine (2017) pointing to likely higher overall costs. Reports from countries that implemented warrantees are disappointing; these were hard to reconcile and probably led to higher prices. A report from Propublica  begins:

More than a decade ago, Italy tried a novel approach to help bring down drug costs: asking pharmaceutical companies to return money to the national health system if some of their medicines failed to work as expected. The effort largely flopped

  1. "March in" and demand that patent-holders offer drugs for less, or seize the patent
    Some countries like Brazil and India have effectively done this- but they are much smaller markets than the US and they tend to be home to generic and not brand manufacturers.   This might be a more effective threat than actual policy.  Some Democrats have suggested that the NIH should exercise its 'march in' rights. Many think this would lead to decreased investment in pharma and less innovation - and such a move seems unlikely in an Administration seeking to diminish the role of government.
     
  2. Allow Medicare to negotiate drug prices
    Right now Medicare Part D is administered through thousands (!) of different plans each of which negotiates with the pharmaceutical industry.  That kind of fragmentation leads to higher prices for Medicare, the largest purchaser of drugs in the country.   Medicare pays more than the Veterans Administration or Medicaid for drugs.  It's hard to imagine disassembling the current Medicare Part D system in the next few years - although it would be easy to imagine some central negotiation for high cost medications that could be excluded from the Medicare Part D plans.
     
  3. Stop drug company direct to consumer advertising
    This would make TV viewing much more pleasurable - but the Supreme Court has decided that commercial speech is protected by the First Amendment, so this would require a constitutional amendment.
     
  4. Direct the FDA to consider cost effectiveness when it approves new medications
    This would require a new statute and new enabling regulations. Countries like the UK which have this in place have found that it does lower access to some new innovative drugs, and this is unpopular.  Perhaps this isn't unpopular at the level of fictional "death panels," but it would be hard to see such legislation gaining broad traction in the next few years.
     
  1. Mandate generic substitution
    Fourteen states mandate that a generic be dispensed where available unless the physician explicitly orders a brand name, and this dramatically increases generic substitution rate.  49 states allow pharmacist generic substitution based on pharmacist discretion - and only Oklahoma prohibits even this.  This battle must be fought state by state, and a small amount of lobbying goes a long way in most state legislatures.
     
  1. Provider risk sharing
    Physicians write prescriptions - and they would pay much more attention to the cost of drugs if their organizations bore financial responsibility for drug costs.  Providers do take risk for drug spending in some accountable care or bundled payment arrangements.  Provider risk sharing could also lead to physicians failing to prescribe valuable but expensive drugs, or "dumping" of patients with known chronic diseases that have expensive drug treatment. 

I'm not confident we'll lower pharmaceutical prices a lot over the next few years- especially given the new genomic drugs in the offing.  And I'm worried that the cost savings from generics might diminish through consolidation in that industry. But I'm heartened by the discussion and the bipartisan concern. Elements of the approach to lowering drug cost inflation that are being discussed now could serve as the foundation to lower costs in the years to come.
  

Kamis, 18 Mei 2017

FDA regs save Medicare $80 billion

.
Today's Managing Health Care Costs Number is $80 billion



The US government dodged an $80 billion dollar bullet by requiring extensive testing before approval of Solanezumab, a new Alzheimer's Disease medication, according to new research in the New England Journal of Medicine. Eli Lilly did two human studies that found the drug no better than placebo, but subgroup analysis suggested that it might be helpful in those with especially early disease.   A trial to examine this, however, also showed no effect of the drug.


That's bad news for Eli Lilly's shareholders -but it's good news for patients who won't be given  (1) false hope (2) inevitable side effects and complications and (3) giant bills.  And it's especially good news for Medicare.  The researchers estimate that the cost of this drug to Medicare alone, were it approved, would have likely been about $80 billion over a four year period.  This good regulatory outcome was only possible because the FDA takes its job seriously and looks to approve only drugs with a credible chance of improving patient health.


The FDA mission would change, though, if it followed the recommendations of a group of scientists and advocates writing for US Against Alzheimers.  This organization (at least partially funded by the pharmaceutical industry) advocates that "the FDA should clarify for the field that a clinically meaningful benefit on a single primary endpoint of cognition or function is a sufficient basis for a New Drug Application filing." In other words, no need for new drugs to improve both cognition and function - improving one alone is enough.   There is already substantial controversy about the current group of Alzheimers drugs approved under the current approach.  These drugs consistently show modest improvement on psychometric testing which some critics feel is not clinically significant.


The current administration is clearly aiming to dramatically decrease regulation.  But easing the rigor of drug approval, in a time when new drugs are always priced at very high prices, has the potential to dramatically increase the cost of health care.   This is especially problematic in the US with direct to consumer advertising, where research shows that marketing



It's most important in the US that the FDA hold firm and not approve drugs that are of no marginal benefit, as once approved marketing (as opposed to research) can drive drugs to be blockbusters.

Rabu, 25 Januari 2017

Duexis: Wasteful prescribed version of OTC meds


Today's Managing Health Care Costs Number is $600 million

 
JAMA Internal Medicine just published a description of the six year journey of Duexis, a drug approved by the FDA for treatment of arthritis for those at risk for gastrointestinal bleeding.   Pretty much no one looks especially good here.

The drug is marked by Horizon Pharmaceuticals, and is a combination of ibuprofen (available over the counter as a generic for pennies a pill) and famotidine (also available over the counter for pennies a pill.)  When it was approved, it cost $158.40 a month (average wholesale cost.)  Today, its wholesale price is $2061 a month! The company has earned over $600 million in revenue from this medication.

Who would prescribe such a drug? 

Physicians would be leery of prescribing such a medicine, for fear that they would be forced to go through a prior authorization program.  Horizon Pharmaceutical's answer: have its employees complete this program!

Who would fill such a prescription?

Patients would be suspicious of a prescription drug that cost this much a month when they could just purchase the components over the counter.  Horizon offers coupons capping member responsibility at $10 - and even gave the drug away for free to those whose pharmacy benefit managers blocked it so that physicians wouldn't stop prescribing it.

These coupons are prohibited for Medicare and Medicaid beneficiaries, right?

Yes - but the pharmaceutical company has arranged for a "charity" to cover patient cost sharing to members of government sponsored health plans.   The pharma donates to this charity - which then undermines the cost sharing requirement of the health plan.   The economics of this are very much like coupons.

What pharmacy benefit manager would have this medicine "on formulary," or would fail to frankly block prescriptions?

The authors report that CVS Caremark recently put Duexis back on its formulary. Presumably, there is a large rebate available - so while the employer or insurer covering the patient pays a high price for the drug, it helps the PBM's bottom line.

Why does the FDA even approve such a bogus drug?

These are the rules.   The FDA is supposed to be promoting safety and innovation -but it is prohibited from considering cost effectiveness or value in its determinations of what medications to approve.

The authors suggest expanding the ban on these coupons which raise the cost of health care - and better regulating copay assistance charities - which at this point use essentially all their resources to subsidize expensive brand name medications.  They would also prohibit specialty pharmacy companies from completing prior authorization paperwork for physicians.   I'd like to see the FDA consider value in its approvals, and further transparency around rebates, which might discourage PBMs from providing coverage for wasteful products like Duexis.